| Eric Rubin | |||||||||||||||||||||||||||||||||||||||||
| Eric J. Rubin, M.D., Ph.D., is a Professor in the Department of Immunology and Infectious Diseases at the Harvard T.H. Chan School of Public Health, an Associate Physician specializing in infectious disease at Brigham and Women’s Hospital, and Editor-in-Chief of the New England Journal of Medicine (NEJM) — USA | |||||||||||||||||||||||||||||||||||||||||
Dr. Rubin is an esteemed microbiologist, recognized for pioneering bacterial genetic tools used to create the next generation of anti-tuberculosis (TB) drugs. His career at Harvard Chan School spans more than 20 years, during which he has primarily focused on Mycobacterium tuberculosis, the pathogen that causes human TB and is the second leading infectious killer of adults worldwide. Rubin, who grew up in Brockton, Massachusetts, and earned MD and PhD degrees at Tufts University, was previously chair of the Department of Immunology and Infectious Diseases and the Irene Heinz Given Professor of Immunology and Infectious Diseases.
He was elected Fellow of the American Academy of Microbiology in 2012. In 2019, he was named editor-in-chief of NEJM and in 2021 he was elected to the National Academy of Medicine, USA.
More info ➡️ https://www.hsph.harvard.edu/rubin-lab/ | |||||||||||||||||||||||||||||||||||||||||